GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Shiller PE Ratio

Nymox Pharmaceutical (Nymox Pharmaceutical) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nymox Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Nymox Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Shiller PE Ratio Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Shiller PE Ratio

For the Biotechnology subindustry, Nymox Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Shiller PE Ratio falls into.



Nymox Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nymox Pharmaceutical's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Nymox Pharmaceutical's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.01/129.8595*129.8595
=-0.010

Current CPI (Sep. 2023) = 129.8595.

Nymox Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.030 98.326 -0.040
201403 -0.070 99.695 -0.091
201406 -0.020 100.560 -0.026
201409 -0.020 100.428 -0.026
201412 -0.010 99.070 -0.013
201503 0.040 99.621 0.052
201506 -0.140 100.684 -0.181
201509 -0.260 100.392 -0.336
201512 -0.110 99.792 -0.143
201603 -0.080 100.470 -0.103
201606 -0.080 101.688 -0.102
201609 -0.070 101.861 -0.089
201612 -0.050 101.863 -0.064
201703 -0.060 102.862 -0.076
201706 -0.050 103.349 -0.063
201709 -0.090 104.136 -0.112
201712 -0.060 104.011 -0.075
201803 -0.050 105.290 -0.062
201806 -0.040 106.317 -0.049
201809 -0.050 106.507 -0.061
201812 -0.050 105.998 -0.061
201903 -0.040 107.251 -0.048
201906 -0.080 108.070 -0.096
201909 -0.040 108.329 -0.048
201912 -0.040 108.420 -0.048
202003 -0.040 108.902 -0.048
202006 -0.040 108.767 -0.048
202009 -0.060 109.815 -0.071
202012 -0.030 109.897 -0.035
202103 -0.030 111.754 -0.035
202106 -0.050 114.631 -0.057
202109 -0.040 115.734 -0.045
202112 -0.030 117.630 -0.033
202203 -0.060 121.301 -0.064
202206 0.010 125.017 0.010
202209 -0.020 125.227 -0.021
202212 -0.010 125.222 -0.010
202303 -0.020 127.348 -0.020
202306 -0.010 128.729 -0.010
202309 -0.010 129.860 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nymox Pharmaceutical  (OTCPK:NYMXF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nymox Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

By GlobeNewswire GlobeNewswire 02-15-2023

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

Nymox Announces $5 Million Registered Direct Offering

By GuruFocusNews GuruFocusNews 03-18-2022